An investigational prostate cancer vaccine has shown potential to improve survival in patients with metastatic castration-resistant prostate cancer (CRPC), according to the results of early clinical evaluations.
In one randomized trial, patients treated with PROSTVAC-VF lived almost 9 months longer than did patients in a control group, and almost twice as many vaccine-treated patients were alive at 3 years.
In all, the investigational immunotherapy has been well tolerated in phase I-II studies involving about
300 patients, setting the stage for a global phase III trial involving 1200 men with asymptomatic or minimally symptomatic metastatic CRPC.
Post Edited (Jerry L.) : 7/4/2013 8:37:05 PM (GMT-6)